BR9611479B1 - Ácidos alfa-iminoidroxÂmicos e carboxÍlicos n-substituÍdos cÍclicos e heterocÍclicos. - Google Patents

Ácidos alfa-iminoidroxÂmicos e carboxÍlicos n-substituÍdos cÍclicos e heterocÍclicos.

Info

Publication number
BR9611479B1
BR9611479B1 BRPI9611479-7A BR9611479A BR9611479B1 BR 9611479 B1 BR9611479 B1 BR 9611479B1 BR 9611479 A BR9611479 A BR 9611479A BR 9611479 B1 BR9611479 B1 BR 9611479B1
Authority
BR
Brazil
Prior art keywords
iminohydroxamic
heterocyclic
alpha
carboxylic acids
unsubstituted cyclic
Prior art date
Application number
BRPI9611479-7A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9611479A (pt
Inventor
Werner Thorwart
Wilfried Schwab
Manfred Schudok
Burkhard Haase
Eckart Bartnik
Klaus-Ulrich Weithmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26020318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9611479(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1995142189 external-priority patent/DE19542189A1/de
Priority claimed from DE1996112298 external-priority patent/DE19612298A1/de
Application filed filed Critical
Publication of BR9611479A publication Critical patent/BR9611479A/pt
Publication of BR9611479B1 publication Critical patent/BR9611479B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
BRPI9611479-7A 1995-11-13 1996-11-04 Ácidos alfa-iminoidroxÂmicos e carboxÍlicos n-substituÍdos cÍclicos e heterocÍclicos. BR9611479B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1995142189 DE19542189A1 (de) 1995-11-13 1995-11-13 Cyclische N-substituierte alpha-Iminohydroxamsäuren
DE1996112298 DE19612298A1 (de) 1996-03-28 1996-03-28 Heterocyclische N-substituierte alpha-Iminohydroxamsäuren
PCT/EP1996/004776 WO1997018194A1 (de) 1995-11-13 1996-11-04 CYCLISCHE UND HETEROCYCLISCHE N-SUBSTITUIERTE α-IMINOHYDROXAM- UND CARBONSÄUREN

Publications (2)

Publication Number Publication Date
BR9611479A BR9611479A (pt) 1999-07-13
BR9611479B1 true BR9611479B1 (pt) 2009-01-13

Family

ID=26020318

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9611479-7A BR9611479B1 (pt) 1995-11-13 1996-11-04 Ácidos alfa-iminoidroxÂmicos e carboxÍlicos n-substituÍdos cÍclicos e heterocÍclicos.

Country Status (20)

Country Link
US (3) US6207672B1 (enExample)
EP (1) EP0861236B2 (enExample)
JP (1) JP4638560B2 (enExample)
KR (1) KR100475206B1 (enExample)
CN (1) CN1131215C (enExample)
AT (1) ATE213232T1 (enExample)
AU (1) AU707707B2 (enExample)
BR (1) BR9611479B1 (enExample)
CA (1) CA2237590C (enExample)
CZ (1) CZ297550B6 (enExample)
DE (1) DE59608740D1 (enExample)
DK (1) DK0861236T4 (enExample)
ES (1) ES2170884T5 (enExample)
HU (1) HU223086B1 (enExample)
MX (1) MX9803753A (enExample)
PL (1) PL186869B1 (enExample)
PT (1) PT861236E (enExample)
RU (1) RU2164914C2 (enExample)
TR (1) TR199800849T2 (enExample)
WO (1) WO1997018194A1 (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69633947T2 (de) * 1995-12-08 2005-12-01 Agouron Pharmaceuticals, Inc., San Diego Zwischenprodukte zur Herstellung von Metallproteinasehemmern
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
FR2748026B1 (fr) * 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0923561B1 (en) * 1996-08-28 2002-10-23 The Procter & Gamble Company Heterocyclic metalloprotease inhibitors
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5977408A (en) * 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6228869B1 (en) 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5962481A (en) * 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
JP2001503400A (ja) * 1996-10-22 2001-03-13 ファルマシア・アンド・アップジョン・カンパニー マトリックス・メタロプロテイナーゼ阻害剤としてのα―アミノスルホニルヒドロキサム酸類
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
SG88737A1 (en) 1996-10-30 2002-05-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
IL130802A0 (en) * 1997-01-23 2001-01-28 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
US6376506B1 (en) 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
WO1999006410A1 (en) * 1997-08-04 1999-02-11 Amgen Inc. Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
DK1021413T3 (da) * 1997-10-06 2003-10-06 Wyeth Corp Fremstilling og anvendelse af ortho-sulfonamido-bicykliske heteroarylhydroxamsyrer som matrixmetalloproteinase- og TACE-inhibitorer
US6130220A (en) * 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
FR2771095B1 (fr) * 1997-11-14 1999-12-17 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6107291A (en) * 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
US6335329B1 (en) 1997-12-19 2002-01-01 Amgen Inc. Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
US6071903A (en) * 1998-01-27 2000-06-06 American Cyanamid Company 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
BR9907746A (pt) * 1998-01-27 2000-10-17 American Cyanamid Co ácidos 2,3,4,5-tetraidro-1h[1,4]-benzodiazepina-3-hidroxâmic os como inibidores de matriz de metaloproteinase
CN1301265A (zh) 1998-05-14 2001-06-27 杜邦药品公司 新的用作金属蛋白酶抑制剂的取代的芳基异羟肟酸
WO2000023443A1 (en) * 1998-10-22 2000-04-27 Akzo Nobel N.V. Tetrahydropyridopyridine derivatives and intermediates for producing the same
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6544984B1 (en) 1999-01-27 2003-04-08 American Cyanamid Company 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
AR022423A1 (es) * 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
GB9903598D0 (en) * 1999-02-18 1999-04-07 Univ Manchester Connective tissue healing
DOP2000000107A (es) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas
GB0011409D0 (en) * 2000-05-11 2000-06-28 Smithkline Beecham Plc Novel compounds
MXPA01013172A (es) * 2001-02-14 2002-08-21 Warner Lambert Co Inhibidores sulfonamida de metaloproteinasa de matriz.
FR2821842B1 (fr) * 2001-03-07 2003-05-09 Servier Lab Nouveaux derives d'inhibiteurs de mettalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6770647B2 (en) 2001-08-17 2004-08-03 Bristol-Myers Squibb Pharma Company Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
WO2003037852A1 (en) 2001-11-01 2003-05-08 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
RU2223703C2 (ru) * 2002-02-13 2004-02-20 Иркутский государственный институт усовершенствования врачей Способ лечения передней хронической нестабильности коленного сустава
DE10209299A1 (de) 2002-03-02 2003-09-18 Aventis Pharma Gmbh Cyclische N-substituierte alpha-Iminocarbonsäuren zur selektiven Inhibierung von Kollagenase
US6716853B2 (en) 2002-03-02 2004-04-06 Aventis Pharma Deutschland Gmbh Cyclic N-substituted alpha-imino carboxylic acids for selective inhibition of collogenase
WO2005021489A2 (en) * 2002-12-23 2005-03-10 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
WO2004060892A1 (ja) * 2002-12-27 2004-07-22 Japan Tobacco Inc. 縮合ｎ含有ヘテロ環化合物及びその医薬用途
DE10300015A1 (de) * 2003-01-03 2004-07-15 Aventis Pharma Deutschland Gmbh Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen
US7205315B2 (en) 2003-09-27 2007-04-17 Sanofi-Aventis Deutschland Gmbh Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases
DE10344936A1 (de) * 2003-09-27 2005-04-21 Aventis Pharma Gmbh Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
US7244845B2 (en) * 2003-11-06 2007-07-17 Sanofi-Aventis Deutschland Gmbh Process for preparing cyclic N-substituted alpha-imino carboxylic acids
DE10351904A1 (de) * 2003-11-06 2005-06-09 Aventis Pharma Deutschland Gmbh Verfahren zur Herstellung von cyclischen N-substituierten alpha-Iminocarbonsäure
DE102004004974A1 (de) * 2004-01-31 2005-08-18 Aventis Pharma Deutschland Gmbh Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen
WO2005108367A1 (en) * 2004-05-03 2005-11-17 Envivo Pharmaceuticals, Inc. Compounds for treatment of neurodegenerative diseases
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln
DE102004031850A1 (de) * 2004-06-30 2006-01-26 Sanofi-Aventis Deutschland Gmbh Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
US7601838B2 (en) * 2004-12-28 2009-10-13 Council Of Scientific And Industrial Research 2-Alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9H-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents
DE102005002500A1 (de) * 2005-01-19 2006-07-27 Sanofi-Aventis Deutschland Gmbh Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen
DE102005015040A1 (de) * 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
CN102579417B (zh) 2005-05-13 2014-11-26 托波塔吉特英国有限公司 Hdac抑制剂的药物制剂
EP1938106A1 (en) * 2005-10-20 2008-07-02 Nordic Bioscience A/S Detection or quantification of aggrecan and its fragments
GB0526257D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2041181B1 (en) * 2006-06-08 2011-05-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Specific protease inhibitors and their use in cancer therapy
EP2182810B1 (en) 2007-08-03 2017-11-08 Nucitec S.A. de C.V. Compositions and methods for treatment and prevention of osteoarthritis
KR20100039300A (ko) 2007-08-07 2010-04-15 애보트 게엠베하 운트 콤파니 카게 세로토닌 5-ｈｔ6 수용체의 조절에 반응하는 장애를 치료하는데 적합한 퀴놀린 화합물
US8293513B2 (en) 2007-12-14 2012-10-23 Georgetown University Histone deacetylase inhibitors
US8420823B2 (en) 2008-04-24 2013-04-16 Msd K.K. Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient
MX2011000512A (es) 2008-07-14 2011-02-24 Novartis Ag Inhibidores selectivos de mmp-12 y mmp-13 basados en acido hidroxamico.
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2947270B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
US20140275108A1 (en) 2013-03-15 2014-09-18 Galderma Research & Development Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
US20190008828A1 (en) 2015-12-28 2019-01-10 The U.S.A., As Represented By The Secretary Department Of Health And Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
ES2695533T3 (es) 2016-02-01 2019-01-08 Galderma Res & Dev Compuestos de bencenosulfonamida, método para su síntesis y uso de los mismos en medicina y cosméticos
US11072583B2 (en) 2017-11-27 2021-07-27 Council Of Scientific & Industrial Research Indole (sulfomyl) n-hydroxy benzamide derivatives as selective HDAC inhibitors
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
CN119565781B (zh) * 2024-12-20 2026-01-02 中南大学 一种金属离子-含氮芳杂环配合物捕收剂及其制备方法和在钨矿浮选中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2125778A1 (en) * 1970-06-02 1971-12-16 Hokuriku Seiyaku Co Ltd , Katsuyama, Fukui (Japan) Isoquinobenzodiazepine derivs - cns depressants hypotensives etc - prepd from isoquinoline-carboxylic acids
TW201303B (enExample) * 1990-07-05 1993-03-01 Hoffmann La Roche
JPH04210675A (ja) † 1990-12-13 1992-07-31 Otsuka Pharmaceut Co Ltd ベンゼン誘導体
US5219851A (en) † 1991-03-05 1993-06-15 Warner-Lambert Company Tetrahydroisoquinoline-type renin inhibiting peptides
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
FR2701480B1 (fr) * 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
NZ288299A (en) † 1994-06-22 1998-06-26 British Biotech Pharm Substituted (hetero)aryl-sulphonylaminomethyl-hydroxamic acid and medicaments
DE10003007C2 (de) * 2000-01-25 2002-06-13 Schunk Metall & Kunststoff Erdungskontakt

Also Published As

Publication number Publication date
US20010011134A1 (en) 2001-08-02
CN1131215C (zh) 2003-12-17
PT861236E (pt) 2002-07-31
ATE213232T1 (de) 2002-02-15
CA2237590C (en) 2011-07-19
US6815440B2 (en) 2004-11-09
HU223086B1 (hu) 2004-03-29
EP0861236A1 (de) 1998-09-02
US6207672B1 (en) 2001-03-27
EP0861236B1 (de) 2002-02-13
JP4638560B2 (ja) 2011-02-23
EP0861236B2 (de) 2006-08-16
HUP9903405A3 (en) 2000-12-28
JP2000500145A (ja) 2000-01-11
TR199800849T2 (xx) 1998-07-21
DE59608740D1 (de) 2002-03-21
MX9803753A (es) 1998-10-31
US20030176432A1 (en) 2003-09-18
DK0861236T3 (da) 2002-05-21
ES2170884T3 (es) 2002-08-16
AU7562496A (en) 1997-06-05
AU707707B2 (en) 1999-07-15
ES2170884T5 (es) 2007-04-01
RU2164914C2 (ru) 2001-04-10
PL326702A1 (en) 1998-10-26
KR19990067685A (ko) 1999-08-25
KR100475206B1 (ko) 2005-12-16
BR9611479A (pt) 1999-07-13
CA2237590A1 (en) 1997-05-22
CZ145398A3 (cs) 1998-08-12
US6573277B2 (en) 2003-06-03
CN1202156A (zh) 1998-12-16
PL186869B1 (pl) 2004-03-31
CZ297550B6 (cs) 2007-02-07
WO1997018194A1 (de) 1997-05-22
HUP9903405A1 (hu) 2000-04-28
DK0861236T4 (da) 2006-12-18

Similar Documents

Publication Publication Date Title
BR9611479A (pt) Acidos alfa-iminoidroxâmicos e carboxílicos N-substituídos cíclicos e heterocíclicos
ATE427300T1 (de) Heterocyclisch substituierte amide als calpainhemmer
BR9712086A (pt) Inibidores1,4-heterocìclicos de metaloproteinases
BR9810841A (pt) Inibidores de metaloprotease alicìclicos
ATE442851T1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
DK1030836T3 (da) Hydroxam- og carboxylsyrederivater der har MMP- og TNF-inhiberende aktivitet
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
BR9205811A (pt) Derivados heterociclicos de aminas ciclicas
BR9712085A (pt) Inibidores de metaloprotease heterocìclicos
DE69432035D1 (de) Saccharinderivate als proteolytische Enzyminhibitoren
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
NO20030724D0 (no) Anvendelse av derivater av valproinsyreamider og 2- valproensyreamider for terapi eller prevensjon av smerte- og/eller hodepinelidelser
DE69613693D1 (de) 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes
YU48698A (sh) Karboksamidni derivati pirolidina, piperidina i heksahidroazepina za lečenje oboljenja na bazi tromboze
ATE264321T1 (de) Zyklisch imid-substituierte pyridylalkan-, alken-,und alkin- carboxamid-derivate, verwendbar als zytostatische und immunosuppressive mittel
EP0699439A3 (en) Treatment of diseases caused by sebum with inhibitors of acyl CoA cholesterol acyltransferase
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
MX9203751A (es) Compuestos de arilo disubstituido que exhiben actividad antagonista selectiva de leucotrieno b4.
EA200000204A1 (ru) Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
DE69500673D1 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
DE69736180D1 (de) Behandlung von manischen erkrankungen
DE3778642D1 (de) Therapeutikum zur behandlung von magengeschwueren.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE PATENTE COM BASE NOS ARTIGOS 8,13,24 E 25 DA LPI NO. 9.279 DE 14/05/1996.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/01/2009, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061552/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132261-03.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: ELI LILLY AND COMPANY (NZ) LIMITED, ELI LILLY AND COMPANY, F. HOFFMANN-LA ROCHE AG., GENENTECH, INC. E HOECHST AKTIENGESELLSCHAFT

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)

Free format text: EXTINCAO DEFINITIVA - ART. 78 INCISO IV DA LPI

B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2234 DE 29/10/2013 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16O, 17O, 18O, 19O E 20O RETRIBUICAO ANUAL.